What's in Eidos Therapeutics, a BridgeBio company's pipeline?

Eidos Therapeutics, a BridgeBio company has 2 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Eidos Therapeutics, a BridgeBio company's portfolio?

Top competitors by shared drug class: Foldrx Pharms, Qilu Pharmaceutical Co., Ltd., Tanabe Pharma Corporation.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/eidos-therapeutics-a-bridgebio-company.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Eidos Therapeutics, a BridgeBio company — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eidos Therapeutics, a BridgeBio company pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
AG10 oral tablet	AG10 oral tablet	phase 3	Transthyretin stabilizer	Transthyretin (TTR)	Cardiovascular / Rare Disease
Acoramidis (AG10)	Acoramidis (AG10)	phase 3	Transthyretin stabilizer	Transthyretin (TTR)	Rare disease / Cardiology

Therapeutic area mix

Cardiovascular / Rare Disease · 1
Rare disease / Cardiology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Foldrx Pharms · 1 shared drug class
Qilu Pharmaceutical Co., Ltd. · 1 shared drug class
Tanabe Pharma Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Eidos Therapeutics, a BridgeBio company:

Cite this brief

Drug Landscape (2026). Eidos Therapeutics, a BridgeBio company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eidos-therapeutics-a-bridgebio-company. Accessed 2026-05-18.